Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up
Authors:
- Alberto PietrangeliAPAlberto Pietrangeli
- Massimo LeandriMLMassimo Leandri
- Edmondo TerzoliETEdmondo Terzoli
- Bruno JandoloBJBruno Jandolo
- Carlo GarufiCGCarlo Garufi
- 1 September 2006
- journal article
- research article
- Published by S. Karger AG in European Neurology
- Vol. 56 (1) , 13-16
Abstract
Oxaliplatin (L-OHP) has become a standard treatment for advanced colorectal cancer and a valid option for patients in the adjuvant setting. Compared with cisplatin, L-OHP has no renal toxicity, only mild hematological and gastrointestinal toxicity, while neurotoxicity is the limiting toxicity. This side effect has been described as a transient distal dysesthesia, enhanced by exposure to cold, and as a dose-related cumulative mild sensitive neuropathy. We studied two groups of patients (18 and 13) with advanced colorectal cancer, treated with median cumulative doses of L-OHP 862 mg/m2 and 1,033.5 mg/m2. All the patients had been evaluated previously, during treatment, after discontinuation and after a long follow-up of 5 years to verify the incidence and the characteristics of the neuropathy induced by this antineoplastic agent. The clinical and neurophysiological examinations showed an acute and transient neurotoxicity and a cumulative dose-related sensory neuropathy in nearly all the patients. The reversibility of these effects was studied. Five patients continue to manifest symptoms and signs of neurotoxicity after a long follow-up, indicating persistence of this peculiar type of neuropathy.Keywords
This publication has 16 references indexed in Scilit:
- High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancerAnnals of Oncology, 2005
- Clinical Management of Oxaliplatin-Associated NeurotoxicityClinical Colorectal Cancer, 2005
- Oxaliplatin-Associated Neuropathy: A ReviewAnnals of Pharmacotherapy, 2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2002
- Acute Oxaliplatin-Induced Peripheral Nerve HyperexcitabilityJournal of Clinical Oncology, 2002
- Chemotherapy-induced peripheral neuropathyJournal of Neurology, 2002
- Comparative Neurotoxicity of Oxaliplatin, Cisplatin, and Ormaplatin in a Wistar Rat Model,Toxicological Sciences, 1998
- Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancerThe Lancet, 1997
- Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional TrialJNCI: Journal of the National Cancer Institute, 1994